Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 5 , ISSUE 1 ( January-June, 2015 ) > List of Articles


The Value of Serum CA19-9 Levels in predicting Extent of Hepatic Fibrosis in Patients with Chronic Hepatitis B

Salimur Rahman, Mamun Al-Mahtab, Mohammad Sayedul Haque, Sharmin Sultana, Ayub Al-Mamun

Citation Information : Rahman S, Al-Mahtab M, Sayedul Haque M, Sultana S, Al-Mamun A. The Value of Serum CA19-9 Levels in predicting Extent of Hepatic Fibrosis in Patients with Chronic Hepatitis B. Euroasian J Hepatogastroenterol 2015; 5 (1):16-18.

DOI: 10.5005/jp-journals-10018-1122

License: CC BY-NC 4.0

Published Online: 01-06-2017

Copyright Statement:  Copyright © 2015; The Author(s).


This cross-sectional observational study was conducted to evaluate the implication of CA19-9 level in predicting the extent of hepatic fibrosis in patients with chronic hepatitis B (CHB). Fifty treatmentnaïve patients with CHB were divided into three groups: group I, patients with no fibrosis (F0; n = 3); group II, patients with mild fibrosis (F1; n = 25) and group III, patients with moderate fibrosis (F3; n = 22). There was no significant (p > 0.05) difference in levels of serum bilirubin, serum alanine aminotransferase, alkaline phosphatase, and alpha fetoprotein among groups I, II and III. Also, mean CA19-9 level did not differ among the three groups. It was observed that, for group II, AUC was 42.6%, sensitivity 52%, specificity 32%, considering cut-off value as 2.8 U/ml to predict F1 liver fibrosis. For group III, AUC was 57.7%, sensitivity 68%, specificity 50% considering cut-off value as 3.2 U/ml to predict F3 fibrosis. The levels of CA19-9 level do not seem to have significant predictive implication to assess hepatic fibrosis.

PDF Share
  1. Sorell MF, Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Ann Intern Med 2009;150(2):104-110
  2. Viral hepatitis B. Lancet 2003;362(9401):2089-2094
  3. Noninvasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006;12(23):3682-3694
  4. Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology 2007;45(1):242-249
  5. Noninvasive biochemical markers of liver fibrosis. J Gastrointestin Liver Dis 2006;15(2):149-159
  6. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 2010;51(4):1445-1449
  7. Noninvasive measures of liver fibrosis. Hepatology 2006;43(2 Suppl 1):S113-S120.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.